Jacqueline Genovese Bova

Jacqueline Genovese Bova is an associate in Goodwin’s Intellectual Property Litigation practice who focuses her practice on representing clients in patent litigation and post-grant invalidity proceedings. Jacqueline’s experience covers a range of technologies, including financial technologies, electrical devices, 3D printers, personal care products. Her experience also includes representing life science companies in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA).

Jacqueline has experience representing companies in all phases of litigation from pre-suit investigation through trial. Some of her engagements include:

• Representing defendant Pass & Seymour in a long-running dispute involving P&S’s core technology, ground-fault circuit interrupters (GFCIs)
• Represented The Gillette Company in litigation filed against Dollar Shave Club, Inc., in which Gillette asserted infringement of a patent directed to razor blade coatings. The matter settled favorably before trial
• Represented Celltrion/Teva in suit under the BPCIA related to biosimilar of Herceptin
• Represented AMAG in a pharmaceutical patent litigation involving AMAG’s Feraheme® product. The matter settled favorably

Pro Bono

Jacqueline maintains an active pro bono practice, including representing clients in §1983 actions and various immigration matters. She also works with the Legal Aid Society’s Exploitation Intervention Project and is involved with Neighborhood Entrepreneur Law Project.

Jacqueline is a member of the Federal Bar Council, the New York State Bar Association, and the New York Intellectual Property Law Association’s Patent Litigation committee.

Jacqueline was a law clerk to the Honorable Ramon E. Reyes, Jr. in the Eastern District of New York.

Jacqueline has been recognized by Best Lawyers: Ones to Watch® in America for her expertise in Litigation – Patent (2023).

While attending Brooklyn Law School, Jacqueline was a fellow of the Trade Secrets Institute. She was also the Executive Notes & Comments Editor for the Brooklyn Journal of International Law, where her article titled “Biosimilar Naming: A Call for Uniformity in a Complex Field” was published.

• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, December 2022
• Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed.," published by Thomson Reuters, January 2021
• Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.," published by Thomson Reuters, November 2019 
• Contributor, “The Biosimilars Litigation Landscape for 2017,” Law360, January 2017